Entrada Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TRDA Nasdaq 8731 https://www.entradatx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entrada Therapeutics Inc

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference - Jun 6th, 2023 11:00 am
Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates - May 15th, 2023 10:03 am
Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - May 13th, 2023 12:03 pm
Entrada Therapeutics Reports First Quarter 2023 Financial Results - May 10th, 2023 11:00 am
We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully - Apr 30th, 2023 2:26 pm
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors - Apr 4th, 2023 11:00 am
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference - Mar 29th, 2023 11:00 am
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner - Mar 8th, 2023 11:02 am
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 6th, 2023 12:00 pm
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference - Feb 27th, 2023 12:00 pm
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) - Feb 9th, 2023 12:00 pm
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable - Jan 9th, 2023 12:00 pm
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More - Dec 22nd, 2022 1:07 pm
Entrada (TRDA) Down on Regulatory Update for DMD Candidate - Dec 20th, 2022 3:03 pm
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy - Dec 19th, 2022 9:30 pm
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More - Dec 14th, 2022 3:24 pm
Entrada (TRDA) Surges on Collaboration With Vertex for DMI - Dec 9th, 2022 6:41 pm
Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy - Dec 8th, 2022 9:12 pm
Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder - Dec 8th, 2022 3:58 pm
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) - Dec 8th, 2022 12:00 pm